FDA Extends Approval for Alirocumab to Lower LDL-C in Pediatric Patients with HeFHÂ
Addressing an Unmet Need in Pediatric Patients with HeFH Heterozygous familial hypercholesterolemia (HeFH) affects about 1 in 313 people—characterized by dangerously high low-density lipoprotein cholesterol (LDL-C) levels. Untreated, it can trigger early heart disease. Detecting and treating it early in pediatric patients can prevent heart problems later. American College of Cardiology/American Heart Association guidelines define acceptable LDL-C […]
FDA Expands Labels for Bempedoic Acid Tablets and Combination Bempedoic Acid and Ezetimibe Tablets to Reduce Cardiovascular RiskÂ
Introduction: Addressing the Need for Improved LDL Management in the US There is a clear need for innovative treatments to combat cardiovascular disease (CVD). Heart disease remains the leading cause of death for men and women. 80% of heart attacks and strokes linked to CVD are preventable with optimal risk factor management. However, every 40 seconds, an individual […]
